Recent studies have confirmed that Pembrolizumab combined with platinum-based chemotherapy, with or without Bevacizumab, can serve as a first-line treatment for persistent, advanced, metastatic, or recurrent cervical cancer with PD-L1 positivity (CPS ≥ 1) [23]. This evidence concerns the gene CD274 and cervical carcinoma.